Pleomorphic liposarcoma is a rare and fast-growing cancer that develops in fat cells, requiring immediate surgical attention, specialized care, and ongoing research into new treatment methods to improve patient outcomes.

How Treatment Can Help Control This Aggressive Cancer

When someone is diagnosed with pleomorphic liposarcoma, the main goal of treatment is to remove the cancer as completely as possible while trying to prevent it from returning or spreading to other parts of the body. This type of cancer is known for growing quickly and has a tendency to come back even after treatment, which is why doctors focus on combining different approaches to give patients the best chance at controlling the disease. The treatment strategy always depends on where the tumor is located, how large it has grown, and whether it has already spread to other areas such as the lungs^[3].

Because pleomorphic liposarcoma is so aggressive compared to other types of liposarcoma, healthcare teams need to act quickly. Standard treatments that have been used for years are still the foundation of care, but researchers are also testing new drugs and methods in clinical trials. These studies give some patients access to innovative therapies that might work better than older options. Understanding both the established treatments and the experimental ones can help patients and their families make informed decisions about care^[1].

Every patient’s situation is unique. Factors like age, overall health, tumor size, and location all influence which treatments doctors recommend. Some people may only need surgery, while others benefit from adding radiation or chemotherapy before or after the operation. The medical team—including surgeons, oncologists, and radiation specialists—work together to create a personalized treatment plan. Long-term follow-up is essential because this cancer can return years after the initial treatment^[3].

Standard Treatment Methods That Doctors Use Today

Surgery is the most important and most reliable treatment for pleomorphic liposarcoma. The goal is to remove the entire tumor along with a surrounding area of healthy tissue, known as a margin. This margin helps ensure that any cancer cells invisible to the naked eye are also removed, reducing the risk of the cancer growing back. Surgeons aim to take out enough tissue to achieve what they call “clear margins,” meaning no cancer cells are detected at the edges of the removed tissue^[3].

In most cases, the tumor can be removed while preserving the limb or organ where it developed. However, when the cancer is very large or wrapped around critical structures like major blood vessels or nerves, more extensive surgery may be necessary. In rare situations, if the tumor cannot be safely removed without causing severe complications, amputation of a limb might be the only option to save the patient’s life. This is an uncommon outcome, but it highlights the serious nature of this disease^[14].

Radiotherapy, also called radiation therapy, is often used alongside surgery. It involves directing high-energy beams at the tumor site to kill any remaining cancer cells. Radiation can be given before surgery to shrink the tumor and make it easier to remove, or after surgery to destroy cells that might have been left behind. When the surgical margin is narrow or positive—meaning cancer cells were found at the edge of the removed tissue—radiation is strongly recommended to lower the chance of recurrence^[3][14].

Chemotherapy uses powerful drugs to kill cancer cells throughout the body. For pleomorphic liposarcoma, chemotherapy may be given before surgery—called preoperative or neoadjuvant chemotherapy—especially when tumors are large or difficult to remove completely. The aim is to shrink the tumor to make surgery safer and more effective. Chemotherapy can also be used after surgery to try to eliminate any remaining cancer cells and reduce the risk of the cancer spreading to distant organs^[3][9].

The most commonly used chemotherapy drugs for soft tissue sarcomas, including pleomorphic liposarcoma, are doxorubicin and combinations involving gemcitabine. Doxorubicin is an older drug that has been a standard treatment for decades. It works by interfering with the cancer cell’s ability to copy its genetic material, ultimately causing the cell to die. Gemcitabine is often combined with another drug called docetaxel to improve effectiveness. These treatments are given through an intravenous line in cycles, with rest periods in between to allow the body to recover^[11].

Chemotherapy can cause significant side effects because it affects not only cancer cells but also healthy cells that divide rapidly, such as those in the bone marrow, digestive tract, and hair follicles. Common side effects include nausea, vomiting, fatigue, hair loss, increased risk of infection due to low white blood cell counts, and mouth sores. Doctors carefully monitor patients during chemotherapy and may adjust doses or provide supportive medications to manage these side effects^[11].

The duration of standard treatment varies. Surgery is a one-time event, though recovery can take weeks to months depending on the extent of the operation. Radiation therapy is typically given five days a week for several weeks. Chemotherapy is administered in cycles, with each cycle lasting a few weeks, and the total treatment course may extend over several months. After completing initial treatment, patients enter a long-term follow-up phase that can last for many years^[3].

Innovative Treatments Being Tested in Clinical Trials

Researchers are actively working to develop better treatments for pleomorphic liposarcoma because standard therapies do not always work as well as doctors would like. Clinical trials are research studies where new drugs, combinations of treatments, or entirely different approaches are tested on patients to see if they are safe and effective. These trials are divided into phases: Phase I studies test safety and determine the right dose; Phase II studies examine whether the treatment shows promise in fighting the cancer; and Phase III studies compare the new treatment directly with the current standard to see which works better^[11].

Two drugs that have shown encouraging results in clinical trials for advanced soft tissue sarcomas, including pleomorphic liposarcoma, are trabectedin and eribulin. These drugs work differently from traditional chemotherapy and have become important options when first-line treatments fail. Trabectedin is a drug originally derived from a marine organism. It works by binding to the DNA of cancer cells and disrupting their ability to repair damage and reproduce. Studies have shown that trabectedin can help control disease progression in patients with advanced sarcomas^[11].

Eribulin is another drug that has demonstrated promising activity against pleomorphic liposarcoma. It belongs to a class of medications that interfere with the structures inside cells that help them divide, called microtubules. By disrupting these structures, eribulin prevents cancer cells from dividing properly, leading to cell death. Clinical trials have indicated that eribulin may offer better outcomes compared to conventional chemotherapy for certain patients with advanced liposarcoma^[11].

Both trabectedin and eribulin have been studied in large clinical trials involving patients from Europe, the United States, and other regions. These studies found that patients treated with these drugs experienced improved control of their disease compared to those receiving standard chemotherapy alone. However, like all cancer treatments, these drugs can cause side effects. Trabectedin may cause liver problems, fatigue, nausea, and low blood cell counts. Eribulin commonly causes fatigue, nerve damage leading to numbness or tingling in hands and feet, and low white blood cell counts^[11].

Beyond these drugs, researchers are exploring other innovative approaches. Targeted therapy is a type of treatment that focuses on specific molecules or pathways that cancer cells need to grow and survive. Scientists have discovered that some pleomorphic liposarcomas have alterations in genes like MDM2 and CDK4, which are involved in controlling cell growth. Drugs that target these molecules are being developed and tested in clinical trials to see if they can stop cancer growth more effectively than traditional chemotherapy^[1][11].

Immunotherapy is another exciting area of research. This approach works by helping the patient’s own immune system recognize and attack cancer cells. Some immunotherapy drugs, called checkpoint inhibitors, block proteins that prevent immune cells from attacking tumors. Early studies are investigating whether these drugs can be effective for pleomorphic liposarcoma, though results are still preliminary^[11].

Clinical trials for pleomorphic liposarcoma are conducted in many locations around the world, including specialized cancer centers in the United States, Europe, and other regions. Patients who are interested in participating in a trial need to meet specific eligibility criteria, which may include the stage of their disease, prior treatments received, and overall health status. Doctors can help patients find open trials that might be suitable for their situation^[11].

Most common treatment methods

• Surgery
  • Complete removal of the tumor along with surrounding healthy tissue (clear margins)
  • Primary treatment for localized pleomorphic liposarcoma
  • In rare cases, amputation may be necessary when tumor is very large or involves critical structures
• Radiotherapy
  • High-energy beams directed at tumor site before or after surgery
  • Recommended when surgical margins are narrow or positive for cancer cells
  • Helps reduce risk of local recurrence
• Chemotherapy
  • Doxorubicin-based regimens as standard first-line treatment
  • Gemcitabine combined with docetaxel as alternative option
  • Preoperative chemotherapy used to shrink large tumors before surgery
  • Postoperative chemotherapy to eliminate remaining cancer cells
• Targeted therapy
  • Trabectedin for advanced disease, works by binding to DNA and disrupting cancer cell repair
  • Eribulin for advanced disease, interferes with cell division structures (microtubules)
  • Drugs targeting MDM2 and CDK4 gene alterations (under investigation in clinical trials)
• Immunotherapy
  • Checkpoint inhibitors being tested in early clinical trials
  • Works by helping immune system recognize and attack cancer cells

After Treatment: The Importance of Long-Term Follow-Up

Once treatment is completed, patients need to attend regular follow-up appointments for many years. This is because pleomorphic liposarcoma has a high risk of coming back—either at the original site or spreading to distant organs like the lungs. During follow-up visits, doctors perform physical examinations, ask about any new symptoms, and order imaging tests such as MRI scans, ultrasounds, or chest X-rays to check for signs of recurrence or spread^[3][9].

The schedule for follow-up appointments is usually more frequent in the first few years after treatment, when the risk of recurrence is highest. A typical schedule might include visits every three to six months for the first two to three years, then less frequently after that. Even many years after treatment, some doctors recommend continued monitoring because late recurrences can occur^[3].

If the cancer does return, treatment options depend on where it has come back and how much it has spread. Sometimes additional surgery is possible. In other cases, patients may need chemotherapy, radiation, or enrollment in a clinical trial testing new therapies. Managing recurrent disease can be challenging, but advances in treatment continue to improve outcomes for many patients^[3].